Publication: Impact of albumin and omeprazole on steady-state population pharmacokinetics of voriconazole and development of a voriconazole dosing optimization model in thai patients with hematologic diseases
Issued Date
2020-09-01
Resource Type
ISSN
20796382
Other identifier(s)
2-s2.0-85090543166
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antibiotics. Vol.9, No.9 (2020), 1-14
Suggested Citation
Buddharat Khan-Asa, Baralee Punyawudho, Noppaket Singkham, Piyawat Chaivichacharn, Ekapun Karoopongse, Methee Chayakulkeeree, Preecha Montakantikul Impact of albumin and omeprazole on steady-state population pharmacokinetics of voriconazole and development of a voriconazole dosing optimization model in thai patients with hematologic diseases. Antibiotics. Vol.9, No.9 (2020), 1-14. doi:10.3390/antibiotics9090574 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/58963
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Impact of albumin and omeprazole on steady-state population pharmacokinetics of voriconazole and development of a voriconazole dosing optimization model in thai patients with hematologic diseases
Abstract
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This study aimed to identify factors that significantly influence the pharmacokinetics of voriconazole in Thai adults with hematologic diseases, and to determine optimal voriconazole dosing regimens. Blood samples were collected at steady state in 65 patients (237 concentrations) who were taking voriconazole to prevent or treat invasive aspergillosis. The data were analyzed using a nonlinear mixed-effects modeling approach. Monte Carlo simulation was applied to optimize dosage regimens. Data were fitted with the one-compartment model with first-order absorption and elimination. The apparent oral clearance (CL/F) was 3.43 L/h, the apparent volume of distribution (V/F) was 47.6 L, and the absorption rate constant (Ka) was fixed at 1.1 h−1 . Albumin and omeprazole ≥ 40 mg/day were found to significantly influence CL/F. The simulation produced the following recommended maintenance doses of voriconazole: 50, 100, and 200 mg every 12 h for albumin levels of 1.5–3, 3.01–4, and 4.01–4.5 g/dL, respectively, in patients who receive omeprazole ≤ 20 mg/day. Patients who receive omeprazole ≥ 40 mg/day and who have serum albumin level 1.5–3 and 3.01–4.5 g/dL should receive voriconazole 50 and 100 mg, every 12 h, respectively. Albumin level and omeprazole dosage should be carefully considered when determining the appropriate dosage of voriconazole in Thai patients.